<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A11H&quot;,&quot;href&quot;:&quot;atc/A11H.md&quot;},{&quot;label&quot;:&quot;biotin&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Biotin_Wang2023_reference&quot;,&quot;label&quot;:&quot;Wang_2023_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_biotin/Biotin_Wang2023_reference.md&quot;,&quot;status&quot;:&quot;extracted \u00b7 stale&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false}]"></div>

# biotin

- **generic name:** biotin
- **ATC codes:** `A11HA05`
- **DrugBank:** [DB00121](https://go.drugbank.com/drugs/DB00121) · **PubChem:** [CID 171548](https://pubchem.ncbi.nlm.nih.gov/compound/171548)
- **molar mass:** 244.311 g/mol (C10H16N2O3S) — DrugBank
- **groups:** approved, investigational, nutraceutical

## About

Biotin, a B vitamin, is used as a vitamin supplement and to treat inherited metabolic disorders. It is widely available as an approved supplement and is also being studied for other uses.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q181354](https://www.wikidata.org/wiki/Q181354) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-05 07:36 | 6:10 | 1/1/0 | 0/0/0 | 0/0/0 | 93,852/12,156 | ollama / qwen3.8:27b-mtp-q8_0 | 6 | 0/6 | 6/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> <span class="pk-badge pk-badge--species" title="Animal study (rat), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">rat</span><br><sub>STALE — current validate: extracted</sub><br><sub>route_to: `engineer_replication`</sub> | [Wang_2023_reference](drugs/drug_biotin/Biotin_Wang2023_reference.md) | ▶ model + simulator | 1-compartment, IV | 2 | Wang Y et al., A picogram BA-ELISA quantification assa…, PLoS neglected tropical dis… (2023) | [10.1371/journal.pntd.0011568](https://doi.org/10.1371/journal.pntd.0011568) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (primary re-run, agreement 0.4). The first reading is what the record holds.">cross-check: partial</span> <span class="pk-badge pk-badge--species" title="Animal study (pig), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">pig</span><br><sub>STALE — current validate: rejected</sub><br><sub>blocking: missing key parameters — none reported by this paper</sub><br><sub>route_to: `human_review`</sub> | [Wang_2001_reference](drugs/drug_biotin/Biotin_Wang2001_reference.md) | — | 1-compartment (no model) | 0 | Wang KS et al., The clearance and metabolism of biotin…, The Journal of nutrition (2001) | [10.1093/jn/131.4.1271](https://doi.org/10.1093/jn/131.4.1271) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=biotin) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| metabolism | lung | `CYP1B1` inducer | DrugBank actor |
| metabolism | skin | `CYP1B1` inducer | DrugBank actor |

<sub>Actors without a tissue in the table: ACACA (cofactor), ACACB (cofactor), HLCS (substrate), MCCC1 (cofactor), MCCC2 (cofactor), PC (cofactor), PCCA (cofactor), PCCB (cofactor), SLC5A6 (substrate), SLC5A8 (substrate).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 182 matched, 63 returned
- **screened:** 4  ·  **relevant:** 1
- **records:** 2  ·  extracted 1  ·  needs_review 0  ·  rejected 1  ·  stale 2
- **scholar-agent fallback query used:** not captured

## Full text wanted

_7 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Wang_2001.pdf` | Wang KS et al., The clearance and metabolism of biotin…, The Journal of nutrition (2001) | popPK | 10 | [10.1093/jn/131.4.1271](https://doi.org/10.1093/jn/131.4.1271) | [11285337](https://pubmed.ncbi.nlm.nih.gov/11285337) | The study reports quantitative pharmacokinetic parameters (half-lives for three phases) for biotin in pigs, with values explicitly stated in the text. |
| `Ogden_2012.pdf` | Ogden A et al., Evaluation of pharmacokinetic/pharmacod…, Antimicrobial agents and ch… (2012) | pd | 5 | [10.1128/AAC.00090-11](https://doi.org/10.1128/AAC.00090-11) | [21986824](https://www.ncbi.nlm.nih.gov/pubmed/21986824) | metadata signals extractable PD data (PK/PD) |
| `Jackson_2015.pdf` | Jackson DN et al., Garcinia xanthochymus Benzophenones Pro…, Antimicrobial agents and ch… (2015) | pd | 4 | [10.1128/AAC.00820-15](https://doi.org/10.1128/AAC.00820-15) | [26195512](https://www.ncbi.nlm.nih.gov/pubmed/26195512) | metadata signals extractable PD data (EC50) |
| `Vlaming_2009.pdf` | Vlaming ML et al., Physiological and pharmacological roles…, Advanced drug delivery revi… (2009) | pgx | 7 | [10.1016/j.addr.2008.08.007](https://doi.org/10.1016/j.addr.2008.08.007) | [19118589](https://www.ncbi.nlm.nih.gov/pubmed/19118589) | metadata signals extractable PGX data (ABCG2, PK/PD-context) |
| `Zhang_2009.pdf` | Zhang H et al., Facile detection of proteins on a solid…, Talanta (2009) | pgx | 7 | [10.1016/j.talanta.2009.04.056](https://doi.org/10.1016/j.talanta.2009.04.056) | [19576433](https://www.ncbi.nlm.nih.gov/pubmed/19576433) | metadata signals extractable PGX data (CYP2E1, PK/PD-context) |
| `Bathum_1998.pdf` | Bathum L et al., A dual label oligonucleotide ligation a…, Therapeutic drug monitoring (1998) | pgx | 5 | [10.1097/00007691-199802000-00001](https://doi.org/10.1097/00007691-199802000-00001) | [9485546](https://www.ncbi.nlm.nih.gov/pubmed/9485546) | metadata signals extractable PGX data (CYP2C19*1) |
| `Litos_2007.pdf` | Litos IK et al., Rapid genotyping of CYP2D6, CYP2C19 and…, Analytical and bioanalytica… (2007) | pgx | 5 | [10.1007/s00216-007-1593-4](https://doi.org/10.1007/s00216-007-1593-4) | [17909762](https://www.ncbi.nlm.nih.gov/pubmed/17909762) | metadata signals extractable PGX data (CYP2D6) |

<sub>queue written 2026-10-05T07:31:45.163520+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Aoki_1995 | not_relevant | 0 | 0 | The paper describes a genetic disease (HCS deficiency) affecting endogenous biotin metabolism, not the pharmacokinetics or pharmacodynamics of exogenous biotin as a drug. |
| PGx | Bathum_1998 | not_relevant | 0 | 0 | The paper describes a genotyping assay for CYP2C19 and uses biotin only as a chemical label for the probe, not as a drug subject to pharmacokinetic or pharmacodynamic analysis. |
| popPK | Ben-Eliezer_2020 | irrelevant | 2 | 0 | The study uses a biotinylated contrast agent (b-BSA-Gd-DTPA) as a probe to image transporter activity in mouse placenta, rather than measuring the pharmacokinetic parameters (CL, V, etc.) of biotin itself. |
| PGx | Bognanni_2024 | not_relevant | 0 | 0 | The paper uses biotin as a targeting ligand for drug delivery and investigates gene expression levels, but does not report pharmacogenomic effects on the PK or PD parameters of biotin itself. |
| popPK | Bond_2018 | irrelevant | 0 | 0 | The study investigates the mechanism of action of a cancer drug (AK306) and uses biotin only as a chemical linker for binding assays, not as a subject of pharmacokinetic analysis. |
| popPK | Bradley_2011 | irrelevant | 0 | 0 | The study characterizes P2X7 receptor pharmacology in rhesus macaques, and biotin is used only as a labeling reagent, not as the subject drug for PK analysis. |
| PD | Bradley_2011 | not_relevant | 0 | 0 | The paper reports receptor pharmacology (EC50/IC50) for P2X7 agonists/antagonists, not a pharmacodynamic exposure-response relationship for the drug biotin. |
| PGx | Brownsey_2006 | not_relevant | 0 | 0 | The paper is a review of acetyl-CoA carboxylase regulation and does not report pharmacogenomic effects on biotin pharmacokinetics or pharmacodynamics. |
| PGx | Báez-Saldaña_2009 | not_relevant | 0 | 0 | The study investigates the physiological effects of biotin deficiency/excess on reproduction in mice and does not report any pharmacogenomic effects (gene variants) on biotin's PK or PD parameters. |
| PGx | Cicalini_2021 | not_relevant | 0 | 0 | The paper describes a genetic disorder (biotinidase deficiency) affecting endogenous metabolism, not the pharmacokinetics or pharmacodynamics of biotin as an administered drug. |
| popPK | Cremonesi_1999 | irrelevant | 2 | 2 | The study reports residence times and dosimetry for radiolabeled biotin used as a pretargeting agent in radioimmunotherapy, not standard pharmacokinetic parameters (CL, V, ka) for biotin as a therapeutic drug. |
| PGx | Dhaini_2003 | not_relevant | 0 | 0 | The paper investigates CYP3A4/5 expression as a biomarker for osteosarcoma prognosis, not the pharmacokinetics or pharmacodynamics of biotin. |
| PGx | Ding_2025 | not_relevant | 0 | 0 | The paper investigates the mechanism of action of Artemetin in asthma and uses biotin only as a labeling reagent, not as the drug of interest for pharmacogenomic analysis. |
| PGx | Donti_2016 | not_relevant | 0 | 0 | The paper describes a genetic disorder of biotin metabolism (holocarboxylase synthetase deficiency) and clinical phenotypes, but does not report pharmacogenomic effects on the pharmacokinetics or pharmacodynamics of biotin as a drug. |
| PGx | Fetsch_2006 | not_relevant | 0 | 0 | The paper investigates the tissue localization of the ABCG2 transporter protein and does not report any pharmacogenomic effects on the pharmacokinetics or pharmacodynamics of biotin. |
| popPK | Foster_2007 | irrelevant | 0 | 0 | The study uses biotin as a chemical labeling reagent (biotinylation) for protein characterization in Cryptococcus neoformans, not as a subject drug for pharmacokinetic analysis. |
| PD | Foster_2007 | not_relevant | 0 | 0 | The paper uses biotin as a chemical labeling reagent for protein isolation and characterization, not as a pharmacological agent, and reports no drug exposure-response or dose-response relationship. |
| popPK | Frankevich_2026 | irrelevant | 0 | 0 | The study is a metabolomic analysis of amino acids in gestational diabetes and does not report pharmacokinetic parameters for biotin. |
| popPK | Goicolea_2022 | irrelevant | 0 | 0 | The paper describes a synthetic polymer for lactoferrin detection where biotin is used only as a chemical linker (LF-biotin conjugate), not as the subject drug for pharmacokinetic analysis. |
| PD | Goicolea_2022 | not_relevant | 0 | 0 | The paper describes a synthetic polymer for lactoferrin detection and reports an EC50 for the assay's binding affinity, not a pharmacodynamic or exposure-response relationship for the drug biotin. |
| PGx | Gow_2020 | not_relevant | 0 | 0 | The paper investigates the mechanism of Dectin-1 S-nitrosylation and its effect on macrophage function, using biotin only as a chemical reagent in a detection assay, not as a drug subject to pharmacogenomic analysis. |
| PGx | Gowda_2022 | not_relevant | 0 | 0 | The paper describes a clinical case of biotinidase deficiency and its treatment, but does not report pharmacogenomic effects on the pharmacokinetic or pharmacodynamic parameters of biotin. |
| popPK | Guo_1993 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of cobra venom cytotoxin, using biotin only as a reagent in the detection assay (biotin-avidin ELISA), not as the subject drug. |
| PGx | Hassan_2023 | not_relevant | 0 | 0 | The paper is a review of episodic ataxia etiologies and treatments, mentioning biotin metabolism defects only as a secondary cause of ataxia, without reporting pharmacogenomic effects on biotin PK/PD. |
| PGx | Hasslacher_1993 | not_relevant | 0 | 0 | The paper describes the regulation of the yeast acetyl-CoA carboxylase gene (ACC1) and its role in fatty acid synthesis, not the pharmacokinetics or pharmacodynamics of the drug biotin in humans. |
| popPK | Jackson_2015 | irrelevant | 0 | 0 | no_text gate: only 133 chars of text extracted (&lt; 400) |
| PD | Jackson_2015 | not_relevant | 0 | 0 | The paper investigates the antifungal activity of Garcinia xanthochymus benzophenones and their interaction with fluconazole, not the pharmacodynamics of biotin. |
| popPK | Jung_2024 | irrelevant | 0 | 0 | The study focuses on biotinylated nanoparticles as an MRI probe for ROS imaging, not on the pharmacokinetics of biotin itself. |
| PGx | Kojima_2006 | not_relevant | 0 | 0 | The paper investigates tissue engineering and cell attachment using the avidin-biotin system, not the pharmacokinetics or pharmacodynamics of biotin as a drug in relation to genetic variants. |
| PGx | Konstantou_2009 | not_relevant | 0 | 0 | The paper describes a genotyping assay method where biotin is used as a chemical label, not as a drug subject to pharmacokinetic or pharmacodynamic analysis. |
| popPK | Krzyzanski_2017 | irrelevant | 0 | 0 | The study uses biotin as a labeling agent to track red blood cell survival, not to characterize the pharmacokinetics of biotin itself. |
| PGx | Litos_2007 | not_relevant | 0 | 0 | The paper describes a genotyping method where biotin is used as a chemical label for detection, not as a drug subject to pharmacokinetic or pharmacodynamic analysis. |
| popPK | Lledó-García_2012 | irrelevant | 0 | 0 | The study models red blood cell life-spans using biotin only as a labeling agent, not as the subject drug for pharmacokinetic analysis. |
| popPK | Mak_2024 | irrelevant | 0 | 0 | The paper focuses on the immunological properties of a vitamin B2 metabolite and uses biotin only as a chemical label for detection, not as a subject drug for pharmacokinetic analysis. |
| PGx | Mao_2011 | not_relevant | 0 | 0 | The paper investigates a genetic variant's effect on Wnt signaling and uses biotin only as a chemical reagent for protein labeling, not as a drug subject to pharmacokinetic or pharmacodynamic analysis. |
| PGx | Meguro_2022 | not_relevant | 2 | 5 | The paper reports a clinical case of safe pregnancy in a patient with a genetic deficiency, but it does not quantify how the genotype alters the pharmacokinetic or pharmacodynamic parameters of biotin. |
| PGx | Mei_2019 | not_relevant | 0 | 0 | The paper investigates the role of lncRNA ZBTB40-IT1 in osteoporosis and bone metabolism, not the pharmacokinetics or pharmacodynamics of the drug biotin. |
| PGx | Menke_2026 | not_relevant | 0 | 0 | The paper investigates protein-protein interactions in Fabry disease using biotin as a chemical labeling tool, not as a drug subject to pharmacogenomic analysis. |
| PGx | Munnich_1981 | not_relevant | 2 | 5 | The paper describes a congenital metabolic disorder (biotin-dependent multiple carboxylase deficiency) and its response to biotin supplementation, but does not report a pharmacogenomic effect of a specific gene variant on the PK/PD of biotin as a drug in a healthy or general population context. |
| PGx | Munnich_1981_2 | not_relevant | 0 | 0 | The paper describes a metabolic disorder (Multiple Biotin-Dependent Carboxylase Deficiency) and its clinical response to biotin, but does not report a pharmacogenomic effect of a specific gene variant on the pharmacokinetics or pharmacodynamics of biotin as a drug. |
| popPK | Niu_2024 | irrelevant | 0 | 0 | The paper studies leucinostatins as antimalarial agents, using biotin only as a chemical tag for a derivative (LB-biotin) and not as the subject drug for pharmacokinetic analysis. |
| popPK | Ogden_2012 | irrelevant | 0 | 0 | no_text gate: only 190 chars of text extracted (&lt; 400) |
| PGx | Omran_2012 | not_relevant | 0 | 0 | The paper investigates the prognostic value of ABCG2 expression in breast cancer and does not report pharmacokinetic or pharmacodynamic effects of biotin. |
| PGx | Opolka-Hoffmann_2021 | not_relevant | 0 | 0 | The paper investigates the impact of immunogenicity (anti-drug antibodies) on the pharmacokinetics of therapeutic antibodies, not the pharmacogenomics of biotin. |
| PGx | Reche-López_2025 | not_relevant | 0 | 0 | The paper investigates biotin as a therapeutic agent for a genetic disorder (BPAN) via epigenetic mechanisms, not how a gene variant affects the pharmacokinetics or pharmacodynamics of biotin. |
| PGx | Ronquillo-Sánchez_2013 | not_relevant | 0 | 0 | The study investigates the effect of biotin on CYP1A enzyme expression in rats, not the effect of a gene variant on biotin's pharmacokinetics or pharmacodynamics. |
| PGx | Ruan_2021 | not_relevant | 0 | 0 | The paper describes the development of a PTH analogue modified with biotin to increase albumin affinity, but does not report any pharmacogenomic effects (gene variants) on the PK or PD of biotin. |
| PGx | Semeraro_2022 | not_relevant | 0 | 0 | The paper reports on the incidence of biotinidase deficiency in a newborn screening program and does not report pharmacokinetic or pharmacodynamic parameters of biotin as a drug. |
| PGx | Shi_2016 | not_relevant | 0 | 0 | The paper investigates the efficacy of a drug delivery system (epirubicin-loaded microbubbles) on cancer cells, where biotin is merely a chemical component of the lipid microbubble structure, not the subject of pharmacogenomic analysis. |
| popPK | Shrestha_2016 | irrelevant | 0 | 0 | The study models red blood cell lifespan using biotin as a labeling agent, not the pharmacokinetics of biotin itself. |
| PGx | Smirnova_2023 | not_relevant | 0 | 0 | The paper describes a proximity labeling technique using biotin to map protein interactions, not the pharmacokinetics or pharmacodynamics of biotin as a drug. |
| popPK | Strating_2022 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of a PDGFRβ-targeting nanobody (VHH1E12) in mice, using biotin only as a labeling reagent for in vitro binding assays, not as the subject drug. |
| PD | Strating_2022 | not_relevant | 3 | 2 | The paper reports binding affinity (EC50) for a nanobody tracer, which is a pharmacological binding parameter, but does not report a pharmacodynamic exposure-response or dose-response relationship for the drug biotin or the nanobody's therapeutic effect. |
| PGx | Thompson_2023 | not_relevant | 0 | 0 | The paper reports a clinical case of a metabolic disorder treated with biotin, but does not report pharmacogenomic effects on biotin's pharmacokinetic or pharmacodynamic parameters. |
| PGx | Tie_2022 | not_relevant | 0 | 0 | The paper investigates the mechanism of a traditional Chinese medicine on hematopoiesis and mentions biotin synthesis as a pathway, but does not report pharmacogenomic effects on biotin PK/PD parameters. |
| PGx | Underwood_2025 | not_relevant | 0 | 0 | The paper uses biotin as a chemical reagent for proximity labeling (TurboID) to identify protein ligands, not as a drug subject to pharmacogenomic analysis. |
| PGx | Vlaming_2009 | not_relevant | 0 | 0 | The paper discusses the physiological role of ABCG2 in secreting biotin into breast milk but does not report a pharmacogenomic effect on the PK or PD parameters of biotin as a drug. |
| popPK | Wang_2023 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of rLj-RGD3 (a toxin protein), using biotin only as a reagent in the BA-ELISA assay, not as the subject drug. |
| PGx | Weyandt_2022 | not_relevant | 0 | 0 | The paper focuses on the genomics and evolution of Wolbachia bacteria in nematodes, not on human pharmacogenomics or the pharmacokinetics of biotin. |
| PGx | Xue_2014 | not_relevant | 0 | 0 | The paper describes a diagnostic method for EGFR mutations using biotin as a chemical label, not a pharmacogenomic study of biotin's pharmacokinetics or pharmacodynamics. |
| PGx | Yamamoto_1993 | not_relevant | 0 | 0 | The paper investigates the cellular localization of CYP2D6 in autoimmune hepatitis and does not report pharmacogenomic effects on the PK or PD of biotin. |
| PGx | Yılmaz_2024 | not_relevant | 0 | 0 | The paper describes a genetic disorder (biotinidase deficiency) and its clinical/genetic spectrum, not the pharmacogenomics of biotin as a drug (i.e., how variants affect biotin's PK/PD). |
| PGx | Zhang_2009 | not_relevant | 0 | 0 | The paper describes a chemiluminescent detection method using a biotin-polymer and does not report any pharmacogenomic effects on biotin pharmacokinetics or pharmacodynamics. |
| PGx | Zhang_2018 | not_relevant | 0 | 0 | The paper describes a biosensor for detecting the CYP2C19*2 allele and uses biotin only as a chemical linker for probe immobilization, not as the drug of interest. |
| popPK | Zhang_2023 | irrelevant | 0 | 0 | The paper describes an immunoassay for semicarbazide where biotin is used only as a derivatizing agent/linker, not as the subject drug for pharmacokinetic analysis. |
| PD | Zhang_2023 | not_relevant | 0 | 0 | The paper describes an immunoassay method for detecting semicarbazide; the reported EC50 values refer to the analytical sensitivity of the assay, not a pharmacodynamic drug-response relationship. |
| PGx | Zhou_2023 | not_relevant | 0 | 0 | The paper investigates the role of the ABCG2 gene in milk fat synthesis in buffaloes, not the pharmacokinetics or pharmacodynamics of biotin as a drug in humans. |
| PGx | Ürey_2023 | not_relevant | 0 | 0 | The paper is a case report on succinate dehydrogenase deficiency and does not report pharmacogenomic effects on the PK or PD of biotin. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-05 07:31 UTC</sub>
